Personal information

No personal information available

Activities

Employment (3)

Gastrointestinal and hepatic specialities clinic : Merida, Yucatan, MX

2019-06-15 to present | Research coordinator (Clinical research)
Employment
Source: Self-asserted source
Luis Alberto Chi-Cervera

Hospital Star Médica Mérida: Merida, Yucatán, MX

2015-02-03 to 2019-06-15 | Clinical research coordinator (Liver Clinic)
Employment
Source: Self-asserted source
Luis Alberto Chi-Cervera

Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubiran: Tlalpan, DF, MX

2015-02-02 to 2017-01-28 | Research assistant (Departament of Gastroenterology)
Employment
Source: Self-asserted source
Luis Alberto Chi-Cervera

Education and qualifications (1)

Universidad Autónoma de Yucatán: Merida, Yucatán, MX

2010-08-02 to 2016-05-25 (Facultad de Medicina)
Education
Source: Self-asserted source
Luis Alberto Chi-Cervera

Works (3)

Sodium-glucose cotransporter 2 inhibitors (SGLT2-I) ameliorate ascites and peripheral edema in patients with cirrhosis and diabetes.

Hepatology (Baltimore, Md.)
2020-04 | Journal article
Contributors: Montalvo-Gordon I; Chi-Cervera LA; García-Tsao G
Source: Self-asserted source
Luis Alberto Chi-Cervera via Europe PubMed Central

Fibroblast growth factor 21 is an early predictor of acute-on-chronic liver failure in critically ill patients with cirrhosis.

Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society
2018-04 | Journal article
Contributors: Ruiz-Margáin A; Pohlmann A; Ryan P; Schierwagen R; Chi-Cervera LA; Jansen C; Mendez-Guerrero O; Flores-García NC; Lehmann J; Torre A et al.
Source: Self-asserted source
Luis Alberto Chi-Cervera via Europe PubMed Central

Low phase angle is associated with the development of hepatic encephalopathy in patients with cirrhosis.

World journal of gastroenterology
2016-12 | Journal article
Source: Self-asserted source
Luis Alberto Chi-Cervera via Europe PubMed Central